19 results about "Biosynthetic enzyme" patented technology

The present invention provides a composition having excellent control efficacy against plant diseases and a method for controlling plant diseases. A composition for controlling a plant disease comprising a compound represented by formula (I)[wherein each symbol represents the same definition as described in the present description] and one or more sterol biosynthetic enzyme inhibitor(s) selected from Group B has excellent control effects on plant diseases; Group B: a group consisting of prothioconazole and mefentrifluconazole.

The invention provides germacradienol biosynthase OsGMS and application of the germacradienol biosynthase OsGMS in prevention and control of pathogenic fungi and weeds, and belongs to the technical field of biosynthesis. The amino acid sequence of the rice germacradienol synthase OsGMS comprises an amino acid sequence as shown in SEQ ID NO: 1, or a functional homologous sequence with at least 75% sequence similarity with the amino acid sequence as shown in SEQ ID NO: 1, or one or more amino acids are added, deleted and replaced in the amino acid sequence as shown in SEQ ID NO: 1, or the amino acid sequence as shown in SEQ ID NO: 1 is a homologous sequence with at least 75% sequence similarity with the amino acid sequence as shown in SEQ ID NO: 2. And the protein formed by the amino acid sequence as shown in SEQ ID NO: 1 has an amino acid sequence with the same function. The encoding gene of the rice germacradienol synthase OsGMS is integrated into a carrier and introduced into a host cell, so that the encoding gene is expressed in the host cell, biosynthesis of germacradienol is realized, the germacradienol has the effect of inhibiting the growth of plant pathogenic fungi and weeds, and therefore, the germacradienol synthase OsGMS can be used for preparing novel biological pesticides capable of inhibiting the fungi and the weeds, and can be used for preparing biological pesticides for inhibiting the fungi and the weeds. And a new technical path is provided for developing environment-friendly agricultural preparations.

The invention relates to application of engineered clostridium butyricum for producing tryptophan in delaying senescence and improving metabolism, and belongs to the technical field of biomedical engineering. The invention discloses an application of engineered clostridium butyricum for expressing tryptophan biosynthetase trpEDCBA in preparation of drugs for delaying senescence, improving metabolism and increasing intestinal beneficial flora. An aging mouse model is constructed, it is found that after the aged mouse orally takes the engineered clostridium butyricum, the muscle strength, the blood glucose homeostasis, the cell metabolism, the cognitive ability and other aspects are remarkably improved, the improvement effect of the engineered clostridium butyricum is better than that of direct taking of butyric acid and tryptophan, the tryptophan-producing clostridium butyricum can be colonized in intestinal tracts for a long time, and the tryptophan-producing effect of the engineered clostridium butyricum is improved. The abundance of effective microbial communities in intestinal tracts is improved, a new tool and means are provided for anti-aging, and good application prospects are achieved.

The invention provides an S-adenosine homocysteine (SAH) analogue, an S-adenosine-L-methionine (SAM) analogue and application thereof. The preparation method comprises the following steps: synthesis of the SAH analogue and a fluoroalkyl SAM analogue, fluoromethylation modification of bioactive molecules by an HMT-MT cyclase cascade reaction system based on the fluoroalkyl SAM analogue, and construction of a fluoro derivative of a clinical drug synthesized by a one-pot enzymatic method. The SAH analogue adopted by the invention can effectively avoid spontaneous degradation of the corresponding SAM analogue, and is used for constructing a cascade reaction system based on HMT-MT cyclase, so that the yield of a fluoromethylation product is increased; it is confirmed that the fluoro-intermediate generated by MT can be accepted by downstream biosynthetase, so that a fluoro-derivative of a clinical drug synthesized by a one-pot enzymic method is constructed.

The present invention discloses a composition for improving cognitive function using a single or complex extract of Acanthopanax koreanum, Astragalus membranaceus, and / or Momordica charantia. The composition increases, in an in-vitro efficacy test, the cell viability of SH-SY5Y cells, which are human-derived neuroblastomas treated with scopolamine that is an oxidative stress-inducing drug, increases the expression of an apoptosis inhibition-related biomarker (Bcl-2), an autophagy-enhancing biomarker (Beclin-1), and an acetylcholine biosynthesis-related enzyme (ChAT), which are neurotransmitters, also increases the expression of the antioxidant-related biomarker HO-1, and increases the inactivation of GSK-3β, which is a therapeutic target for Alzheimer's disease, and furthermore, even in an in-vivo efficacy test, increases the expression of Bcl-2, Beclin-1, ChAT, and HO-1 in the hippocampus and cerebrum of an animal model with reduced cognitive function and memory induced by administration of scopolamine, and inhibits the expression of iNOS, which is an enzyme involved in NO biosynthesis that induces tissue damage.

To provide a technique for inducing early flowering of a gramineous plant.SOLUTION: The method for inducing early flowering comprises culturing a gramineous plant (e.g. rice variety'Kyo no Yume') having a functionally deficient mutation of a gene encoding gibberellin biosynthetic enzyme protein GA3ox2 under gibberellin treatment and a method for inducing early flowering of the gramineous plant comprising gibberellin is provided.SELECTED DRAWING: Figure 3

The invention involves the provision of recombinant algal mutants that have a genetic modification to a nucleic acid sequence encoding a trehalose biosynthetic enzyme, and / or a genetic modification to a nucleic acid encoding an RNA binding domain And in some embodiments either of these algal mutants can further have a genetic mutation to a nucleic acid sequence encoding an SGI1 polypeptide. Attenuation of one, two, or all three of these genes results in a mutant organism with increased lipid productivity. It was also discovered that one, two, three, or more genetic mutations can be accumulated or “stacked” in a particular mutant cell or organism to result in further increases in the production of lipid products. The lipid products of these mutants are useful as biofuels or for other specialty chemical products.

The invention relates to the technical field of microorganisms, and discloses recombinant yeast for efficiently synthesizing a GPP derivative compound as well as a construction method and application of the recombinant yeast. The recombinant yeast strain takes a yeast strain as an original strain, and is obtained by introducing a target coding gene into a cell nucleus; the target coding gene comprises a coding gene of a mevalonic acid (MVA) synthetic pathway enzyme, a coding gene of a farnesyl diphosphate synthase mutant and a coding gene of optional geranyl diphosphate derivative synthase. According to the invention, an MVA pathway and a key enzyme are introduced into a cell nucleus, so that competitive consumption of a sterol synthesis pathway in cytoplasm on geranyl diphosphate (GPP) is effectively avoided, and efficient synthesis of the GPP derivative compound is realized. Besides, the recombinant yeast strain disclosed by the invention can be combined with a reported peroxisome platform to construct a double-organelle platform strain, so that the yield of GPP derivative compounds can be further increased.

The present invention relates to methods of producing compounds of interest in a recombinant microorganism. In particular, the present invention relates to using a recombinant microorganism comprising a heterologous nucleic acid encoding one or more mycosporine-like amino acid (MAA) biosynthetic enzymes (e.g., MysH) to produce compounds of interest. Compositions comprising compounds produced using such methods are also provided herein. The present disclosure also provides methods of preventing sunburn, cancer, and chronic inflammatory diseases by administering such compositions to subjects in need thereof.

The present application relates to a kind of doped Holoferritin nanoenzymes and its biosynthesis method and application, belong to the cross technical field of nanobiology, biosynthetic enzyme, the doped Holoferritin nanoenzymes except with the protein basic characteristic of Holoferritin nanoenzymes, also have class oxidase activity and class peroxidase activity, can improve the problem of current ferritin cavity doping scheme difficulty, catalytic activity single, in complex or specific catalytic scene with application potential.

The invention provides a catalytic tripdiolide biosynthase and application of the catalytic tripdiolide biosynthase to catalysis of C-2 site hydroxylation of an abietane type diterpenoid compound, the enzyme is cytochrome P450 oxidase CYP71BE272, and the invention further relates to polynucleotide CYP71BE272 for encoding the enzyme, and the polynucleotide CYP71BE272 is used for encoding the tripdiolide biosynthase and application of the catalytic tripdiolide biosynthase to catalysis of C-2 site hydroxylation of the abietane type diterpenoid compound. Catalytic experiments prove that the enzyme has the function of catalyzing hydroxylation of a triptolide C2 site to form triptolide. The tripdiolide biosynthesis can be realized by utilizing a saccharomyces cerevisiae system and by virtue of simple compound enrichment and separation, the invention provides a green and efficient method for obtaining tripdiolide, and the method has important significance for relieving the current scarce market demand and further development and utilization of the compound.

This invention belongs to the field of synthetic biology and discloses tetracycline compounds modified with a polysaccharide group at the C8 position, their biosynthetic methods, and applications. The tetracycline compounds with a polysaccharide group modification at the C8 position provided by this invention have a novel structure; the trisaccharide and hexasaccharide groups present at the C8 position are not found in known tetracycline natural products or tetracycline skeleton antibiotics. The biosynthetic method involves using a polysaccharide group derived from *Streptomyces rubrum*. ech Gene clusters, in which mis This invention expresses the gene cluster in the *Streptomyces micranthum* host, fully utilizing the different biosynthetic enzymes contained in two similar but different tetracycline natural product biosynthetic gene clusters to synthesize novel compounds that neither host bacterium can synthesize. These compounds exhibit significant inhibitory activity against *Staphylococcus aureus*, *Enterococcus faecalis*, and *Enterococcus faecium*. This invention provides new candidate compounds for the innovative development of tetracycline-based antibacterial drugs and is of great significance to the development of microbial drug resources.

To provide a method for screening a DNA sequence by which the optimum combination of the expression intensities of individual genes can readily be found even when the optimum combination of the expression intensities of the individual genes in a cluster containing a plurality of genes encoding a multimodule type biosynthetic enzyme is unknown.SOLUTION: The method for screening a DNA sequence of the present invention comprises at least the steps of: (a) assembling DNA fragments using the OGAB method to prepare a plasmid containing a plurality of DNA fragments encoding multimodular biosynthetic enzymes; (b) transforming the plasmid into a host cell to allow the host cell to produce the multimodular biosynthetic enzymes; and (c) screening a plasmid containing a DNA fragment based on the properties of the produced multimodular biosynthetic enzymes or the properties of the transformed host cell.SELECTED DRAWING: None

The invention relates to the field of gene engineering, in particular to saccharomyces cerevisiae gene engineering bacteria for producing verbascoside and echinacoside through de novo synthesis and application of the saccharomyces cerevisiae gene engineering bacteria. The genetically engineered bacterium contains a coded chorismate synthase mutant, a chorismate mutase mutant, shikimic acid kinase, cytochrome b5, glucose-6-phosphate-dehydrogenase, aromatic acetaldehyde synthase, UDP (User Datagram Protocol) glucosyltransferase, tyrosine ammonia lyase, phenylalanine ammonia lyase, cinnamate hydroxylase, 4-coumaric acid: coenzyme A ligase and acyltransferase. The invention relates to a gene encoding a UDP glucosyltransferase mutant, and more preferably, the gene encoding the UDP glucosyltransferase mutant comprises genes of a UDP glucosyltransferase mutant, a UDP glucosyltransferase mutant, a UDP glucosyltransferase mutant and a UDP glucosyltransferase mutant. Under a shake flask condition, verbascoside produced by the strain reaches 231 mg / L, echinacoside produced by the strain reaches 184 mg / L, and the strain has industrial application potential.

Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to express novel recombinant genes encoding steviol biosynthetic enzymes and UDP-glycosyltransferases (UGTs). Such microorganisms, plants, or plant cells can produce steviol or steviol glycosides, e.g., rubusoside or Rebaudioside A, which can be used as natural sweeteners in food products and dietary supplements.

This invention relates to methods of producing triterpenoids using one or more of (i) Saponaria officinalis β-amyrin synthase (SobAS) (ii) S. officinalis C28 oxidase (SoC28) (iii) S. officinalis C28C16 oxidase (SoC28C16)(iv) S. officinalis C23 oxidase (SoC23); (v) S. officinalis QA 3-O glucuronosyl transferase SoCSL; (vi) S. officinalis QA-GlcA SoC3Gal; (vii) S. officinalis QA-GlcA-Gal x SoC3Xy; (vii) S. officinalis QA-Tri fucosyl transferase SoC28Fu (ix) S. officinalis QA-TriF rhamnosyl transferase SoC28Rha (x) S. officinalis QA-TriFR xyl SoC28Xul1; (xi) S. officinalis QA-TriFRX xyl SoC28Xyl2; (xii) S. officinalis QA-TriFRXX quinovosyl SoGH1 and (xiii) A. officinalis QA-TroF(Q)RXX acetyl SoBAHD1 polypeptide. Methods, host cells, isolated polypeptides, nucleic acids, and plants are provided.

To provide a symbiont forming inoculum which is capable of imparting one or more desired traits into a target plant without introducing heterogeneous DNA into the entire plant.SOLUTION: Provided is a symbiont forming inoculum comprising a polynucleotide encoding a phytohormone biosynthetic enzyme and a polynucleotide of interest, the phytohormone biosynthetic enzyme being at least one cytokinin biosynthetic enzyme and / or an auxin biosynthetic enzyme.SELECTED DRAWING: Figure 1

The invention relates to a recombinant bacterium capable of producing ectoine, L-theanine and collagen III at high yield and application of the recombinant bacterium, and belongs to the technical field of genetic engineering. The recombinant bacteria obtained by introducing plasmids containing ectoine biosynthetase genes and plasmids containing gamma-glutamine synthetase genes and III type collagen genes into corynebacterium glutamicum ATCC 13032 can be used for simultaneously producing ectoine, L-theanine and III type collagen at high yield. Meanwhile, an aspartate kinase gene and an aspartate semialdehyde dehydrogenase gene are connected to a plasmid containing an ectoine biosynthase gene, so that the yield of ectoine is increased. The recombinant bacteria obtained by the transformation can be used for simultaneously synthesizing 25.1 g / L of ectoine, 9.82 g / L of L-theanine and 356 mg / L of III type collagen after being subjected to fermentation culture.

The application discloses a preparation process of high-activity supramolecular assembly microspheric PDRN and belongs to the field of cosmetic raw material preparation, and contains two stages of PDRN biosynthesis-enzymatic decoupling extraction refinement and supramolecular assembly microspherization. First, PDRN precursors are synthesized through fermentation of genetically engineered Escherichia coli, combined with salmon testis enzyme-assisted extraction, and purified through macroporous resin-ultrafiltration membrane combination to obtain high-purity PDRN pure product; then, through intermolecular hydrogen bonds and hydrophobic interaction, self-assembly is realized by using amphiphilic cyclodextrin derivatives and PEG-PLA as carriers to realize PDRN microspherization, and a crosslinking agent is not needed in the whole process. The prepared microspheric PDRN has a purity of 95%, a particle size of 100-300 nm, an encapsulation rate of 85%, an activity retention rate of 90%, excellent sustained release and stability, no skin irritation, and is suitable for various cosmetic formulations, and the process equipment is conventional, easy to be industrialized, the raw material utilization rate is high, and the process is green and environmentally-friendly.